Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells

Carcinogenesis. 1994 Apr;15(4):695-700. doi: 10.1093/carcin/15.4.695.

Abstract

During selection for methotrexate (MTX) resistance the metastatic subclone BSp73ASML of a spontaneous rat adenocarcinoma and a metastatic transfectant containing the metastogene META-1 underwent amplification of the dihydrofolate reductase (DHFR) gene at accelerated rates in contrast to non-metastatic but closely related BSp73AS cells. A four log increase in MTX resistance was associated with a 16-fold amplification and increased expression of the DHFR gene. The capacity for gene amplification in metastatic BSp73ASML cells was correlated with a deletion in the p53 gene and enhanced expression of the oncogene c-myc due to a 10-fold amplification of the myc gene. Increased expression of Ki-ras and c-raf in the non-metastatic BSp73AS cells seems to confer tumorigenicity but not permissivity for gene amplification.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Animals
  • DNA, Neoplasm / genetics
  • Drug Resistance
  • Gene Amplification / drug effects
  • Genes, myc
  • Genes, p53
  • Genes, ras
  • Methotrexate / pharmacology*
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins c-raf
  • Rats
  • Tetrahydrofolate Dehydrogenase / genetics*
  • Tumor Cells, Cultured

Substances

  • DNA, Neoplasm
  • Proto-Oncogene Proteins
  • Tetrahydrofolate Dehydrogenase
  • Proto-Oncogene Proteins c-raf
  • Methotrexate